Back to top
more

Signal Genetics, Inc. (MGEN)

(Delayed Data from NSDQ)

$2.83 USD

2.83
113,835

+0.05 (1.80%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.82 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.

Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q3 revenues increase year over year.

Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

by Zacks Equity Research

Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.

Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up

by Zacks Equity Research

Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.

Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 29.41% and -74.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Signal Genetics, Inc. (MGEN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Jun 18, 2020

by Zacks Equity Research

Companies in the news are: WATT, ARMP, MGEN, CEMI

Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -24.00% and -9.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Jan 31, 2020

by Zacks Equity Research

Companies In The News Are: BGG, INO, MDLZ, MGEN

Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -20.00% and -58.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -8.57% and -72.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -6.45% and -69.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 9.38% and -50.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Signal Genetics (MGEN) Run Higher on Strong Earnings Estimate Revisions?

by Zacks Equity Research

Signal Genetics (MGEN) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

    2 Biotech Stocks with Month-Long Upward Estimate Revisions

    by Zacks Equity Research

    Although the biotech sector initially picked up this year, it witnesses a correction since October. However, it is a good idea to select stocks witnessing positive estimate revisions for a month now.

      Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

      by Zacks Equity Research

      Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

        Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks

        by Zacks Equity Research

        Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.